Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Wells Fargo to hold a virtual conference » 08:13
04/07/20
04/07
08:13
04/07/20
08:13
ADAP

Adaptimmune

$3.01 /

+0.38 (+14.45%)

, AFMD

Affimed N.V.

$1.83 /

+0.23 (+14.38%)

, AKCA

Akcea Therapeutics

$15.74 /

+1.19 (+8.18%)

, AGTC

Applied Genetic

$3.38 /

+0.4 (+13.42%)

, ARNA

Arena Pharmaceuticals

$47.33 /

+2.24 (+4.97%)

, AUTL

Autolus Therapeutics

$6.35 /

+1 (+18.69%)

, AVRO

Avrobio

$14.99 /

+1.62 (+12.12%)

, BLUE

Bluebird Bio

$43.52 /

+1.64 (+3.92%)

, CYAD

Celyad

$7.92 /

+0.92 (+13.14%)

, CRSP

Crispr Therapeutics

$42.26 /

+2.81 (+7.12%)

, GRTS

Gritstone Oncology

$6.62 /

+0.36 (+5.75%)

, IMV

IMV Inc.

$1.69 /

+0.03 (+1.81%)

, INFI

Infinity Pharmaceuticals

$0.89 /

+0.0875 (+10.94%)

, JNCE

Jounce Therapeutics

$4.96 /

+0.68 (+15.89%)

, MEIP

MEI Pharma

$1.55 /

+0.07 (+4.73%)

, MNTA

Momenta

$27.93 /

+3.93 (+16.38%)

, MYOK

MyoKardia

$47.96 /

+1.52 (+3.27%)

, QURE

uniQure

$47.77 /

+2.39 (+5.27%)

, VYGR

Voyager Therapeutics

$8.92 /

+0.79 (+9.72%)

2020 Wells Fargo Biotech…

2020 Wells Fargo Biotech Virtual Corporate Access Day will be held on April 7. Webcast Link

ShowHide Related Items >><<
ADAP Adaptimmune
$3.01 /

+0.38 (+14.45%)

10/23/19
Adaptimmune management to meet with SunTrust
08/02/19
Fly Intel: Top five analyst downgrades
08/02/19 Guggenheim
Adaptimmune downgraded to Neutral on low near-term visibility at Guggenheim
08/01/19 Guggenheim
Adaptimmune downgraded to Neutral from Buy at Guggenheim
AFMD Affimed N.V.
$1.83 /

+0.23 (+14.38%)

AKCA Akcea Therapeutics
$15.74 /

+1.19 (+8.18%)

01/22/20 Stifel
Akcea LICA data look 'solid,' as expected, says Stifel
10/08/19 BMO Capital
Akcea Therapeutics price target lowered to $39 from $43 at BMO Capital
10/07/19 Stifel
Pfizer deal a 'solid, unexpected' win for Akcea Therapeutics, says Stifel
10/07/19
Akcea Therapeutics upgraded to Outperform on Pfizer partnership at Wells Fargo
AGTC Applied Genetic
$3.38 /

+0.4 (+13.42%)

02/12/20 Roth Capital
Applied Genetic in position to execute after cash raise, says Roth Capital
01/28/20
Fly Intel: Top five analyst initiations
01/27/20 Roth Capital
Applied Genetic initiated with a Buy at Roth Capital
01/09/20 BMO Capital
Applied Genetic price target raised to $16 from $9 at BMO Capital
ARNA Arena Pharmaceuticals
$47.33 /

+2.24 (+4.97%)

03/31/20 Guggenheim
Guggenheim starts Arena at Buy on 'pipeline-in-a-product' etrasimod
03/31/20 Guggenheim
Arena Pharmaceuticals initiated with a Buy at Guggenheim
03/26/20 BofA
Arena Pharmaceuticals upgraded to Buy on recent selloff at BofA
03/26/20 BofA
Arena Pharmaceuticals upgraded to Buy from Neutral at BofA
AUTL Autolus Therapeutics
$6.35 /

+1 (+18.69%)

02/18/20 H.C. Wainwright
Now the time to get long Autolus Therapeutics, says H.C. Wainwright
09/23/19 Needham
Autolus Therapeutics initiated with a Buy at Needham
09/23/19 Needham
Autolus Therapeutics initiated with a Buy at Needham
09/12/19 H.C. Wainwright
Autolus' Woodford overhang in the rearview, says H.C. Wainwright
AVRO Avrobio
$14.99 /

+1.62 (+12.12%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
BLUE Bluebird Bio
$43.52 /

+1.64 (+3.92%)

03/27/20 BMO Capital
Bluebird Bio price target lowered to $107 from $132 at BMO Capital
03/26/20
Bluebird Bio upgraded to Buy from Hold at Stifel
03/26/20 Stifel
Bluebird Bio upgraded to Buy from Hold at Stifel
03/26/20 Piper Sandler
Bluebird Bio price target lowered to $75 from $85 at Piper Sandler
CYAD Celyad
$7.92 /

+0.92 (+13.14%)

03/26/20 Wells Fargo
Celyad price target lowered to $20 from $44 at Wells Fargo
03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
CRSP Crispr Therapeutics
$42.26 /

+2.81 (+7.12%)

04/01/20 Piper Sandler
Crispr Therapeutics study halts not unexpected, says Piper Sandler
03/04/20 Stifel
Crispr Therapeutics initiated with a Hold at Stifel
02/13/20 Piper Sandler
Crispr Therapeutics ended year with $943M in cash, says Piper Sandler
02/03/20 Evercore ISI
Evercore ISI downgrades Crispr Therapeutics, questions relative valuation
GRTS Gritstone Oncology
$6.62 /

+0.36 (+5.75%)

07/26/19
Fly Intel: Top five analyst initiations
07/25/19 Baird
Gritstone Oncology initiated with an Outperform at Baird
IMV IMV Inc.
$1.69 /

+0.03 (+1.81%)

04/01/20 B. Riley FBR
IMV Inc. downgraded to Neutral from Buy at B. Riley FBR
03/18/20 Raymond James
IMV Inc. downgraded to Market Perform from Outperform at Raymond James
02/28/20 B. Riley FBR
IMV Inc. selloff this weekend is overdone, says B. Riley FBR
02/25/20 H.C. Wainwright
IMV's DeCidE1 results 'quite encouraging,' says H.C. Wainwright
INFI Infinity Pharmaceuticals
$0.89 /

+0.0875 (+10.94%)

11/18/19 B. Riley FBR
Infinity Pharmaceuticals resumed with a Buy at B. Riley FBR
06/27/19
Fly Intel: Top five analyst initiations
06/27/19
Oppenheimer bullish on Infinity Pharmaceuticals, initiates with an Outperform
06/26/19 Oppenheimer
Infinity Pharmaceuticals initiated with an Outperform at Oppenheimer
JNCE Jounce Therapeutics
$4.96 /

+0.68 (+15.89%)

03/25/20 Raymond James
Jounce upgraded to Strong Buy ahead of cancer data at Raymond James
03/25/20 Raymond James
Jounce Therapeutics upgraded to Strong Buy from Outperform at Raymond James
MEIP MEI Pharma
$1.55 /

+0.07 (+4.73%)

MNTA Momenta
$27.93 /

+3.93 (+16.38%)

04/02/20 H.C. Wainwright
Momenta's Vivacity-MG still on track despite COVID-19, says H.C. Wainwright
04/02/20 Piper Sandler
Piper Sandler says enrollment delays already priced into Momenta shares
03/12/20
Fly Intel: Top five analyst initiations
03/12/20 Goldman Sachs
Momenta initiated with a Neutral at Goldman Sachs
MYOK MyoKardia
$47.96 /

+1.52 (+3.27%)

03/31/20 Cantor Fitzgerald
MyoKardia's MAVERICK data keeps Cantor Fitzgerald 'positive'
02/11/20 Credit Suisse
MyoKardia price target raised to $82 from $77 at Credit Suisse
02/07/20 JPMorgan
MyoKardia shares can reach $100-$115 on positive data, says JPMorgan
01/27/20 Guggenheim
Guggenheim has high conviction in MyoKardia trial after cardiologist survey
QURE uniQure
$47.77 /

+2.39 (+5.27%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
VYGR Voyager Therapeutics
$8.92 /

+0.79 (+9.72%)

03/30/20 Nomura Instinet
Voyager Therapeutics price target lowered to $16 from $37 at Nomura Instinet
03/19/20
Fly Intel: Top five analyst initiations
03/19/20 Benchmark
Benchmark starts Voyager Therapeutics at Buy with $18 price target
03/19/20 Benchmark
Voyager Therapeutics initiated with a Buy at Benchmark
Recommendations
Celyad price target lowered to $20 from $44 at Wells Fargo » 08:18
03/26/20
03/26
08:18
03/26/20
08:18
CYAD

Celyad

$7.99 /

+2.25 (+39.20%)

Wells Fargo analyst Jim…

Wells Fargo analyst Jim Birchenough lowered the firm's price target on Celyad to $20 from $44 following review of Q4 results for the company's novel CAR-T pipeline and platform. The analyst keeps an Overweight rating on the shares.

ShowHide Related Items >><<
CYAD Celyad
$7.99 /

+2.25 (+39.20%)

03/25/20 H.C. Wainwright
Celyad price target lowered to $37 from $43 at H.C. Wainwright
07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
Recommendations
Celyad price target lowered to $37 from $43 at H.C. Wainwright » 13:04
03/25/20
03/25
13:04
03/25/20
13:04
CYAD

Celyad

$7.25 /

+1.51 (+26.31%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Edward White lowered the firm's price target on Celyad to $37 from $43 and keeps a Buy rating on the shares. White said that the company's reported 2019 revenue estimate was in-line with his estimate while EPS was above his estimate. The analyst noted that preliminary results from the THINK trial's expansion cohort are now expected in the second half of the year, compared to the prior timing of late first half, due to enrollment delays caused by the COVID-19 pandemic. White added that despite the COVID-19 related delays, he continues to believe the company could decide by year end 2020 on whether to pursue the THINK or DEPLETHINK for CYAD-01.

ShowHide Related Items >><<
CYAD Celyad
$7.25 /

+1.51 (+26.31%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
Hot Stocks
Celyad names Stephen Rubino as Chief Business Officer » 05:55
03/02/20
03/02
05:55
03/02/20
05:55
CYAD

Celyad

$8.68 /

-0.18 (-2.03%)

, NVS

Novartis

$83.99 /

-2.06 (-2.39%)

Celyad (CYAD) announced…

Celyad (CYAD) announced that Stephen Rubino, Ph.D., has been appointed Chief Business Officer. Dr. Rubino has more than 25 years of strong commercial and strategic development experience in the pharmaceutical and biotechnology industry, including 17 years at Novartis (NVS). He will serve on the executive leadership team and will lead business and corporate development for Celyad.

ShowHide Related Items >><<
CYAD Celyad
$8.68 /

-0.18 (-2.03%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
NVS Novartis
$83.99 /

-2.06 (-2.39%)

02/26/20 Bernstein
Regeneron upgraded to Outperform from Market Perform at Bernstein
02/26/20 Canaccord
Regeneron competitive concerns decrease, Canaccord upgrades to Buy
02/26/20 Credit Suisse
Regeneron price target raised to $510 from $420 at Credit Suisse
02/26/20 Baird
Regeneron downgraded to Neutral from Outperform at Baird
Conference/Events
SVB Leerink to hold a conference » 04:55
02/27/20
02/27
04:55
02/27/20
04:55
ABBV

AbbVie

$88.40 /

-0.73 (-0.82%)

, BBIO

BridgeBio

$32.67 /

+0.72 (+2.25%)

, CYAD

Celyad

$9.78 /

-0.17 (-1.71%)

, DCPH

Deciphera

$54.35 /

+0.495 (+0.92%)

, FULC

Fulcrum Therapeutics

$18.50 /

+2.28 (+14.06%)

, GH

Guardant Health

$81.52 /

+5.75 (+7.59%)

, IMVT

Immunovant

$14.87 /

+0.015 (+0.10%)

, INGN

Inogen

$47.88 /

+5.92 (+14.11%)

, LMAT

LeMaitre

$29.53 /

-0.35 (-1.17%)

, NUAN

Nuance

$22.27 /

+0.17 (+0.77%)

, NVCN

Neovasc

$2.70 /

+0.04 (+1.50%)

, RARE

Ultragenyx

$55.71 /

+0.88 (+1.60%)

, QURE

uniQure

$53.57 /

-0.96 (-1.76%)

, SELB

Selecta Biosciences

$4.21 /

+0.215 (+5.38%)

, VCEL

Vericel

$15.06 /

-1.645 (-9.85%)

, RDUS

Radius Health

$17.87 /

-0.06 (-0.33%)

, PODD

Insulet

$180.00 /

-17.03 (-8.64%)

, RDHL

RedHill Biopharma

$4.68 /

+0.12 (+2.63%)

, TCRR

TCR2 Therapeutics

$13.67 /

+0.36 (+2.70%)

, ORGO

Organogenesis

$4.23 /

-0.14 (-3.20%)

, OSMT

Osmotica Pharmaceuticals

$5.45 /

+0.32 (+6.24%)

, MLND

Millendo Therapeutics

$8.75 /

+0.08 (+0.92%)

, ITCI

Intra-Cellular

$22.24 /

-0.79 (-3.43%)

, IFRX

InflaRx

$4.84 /

+0.69 (+16.63%)

, STSA

Satsuma Pharmaceuticals

$26.10 /

-0.22 (-0.84%)

, MIRM

Mirum Pharmaceuticals

$16.53 /

-0.81 (-4.67%)

9th Annual Global…

9th Annual Global Healthcare Conference will be held in New York on February 25-27.

ShowHide Related Items >><<
ABBV AbbVie
$88.40 /

-0.73 (-0.82%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
BBIO BridgeBio
$32.67 /

+0.72 (+2.25%)

02/19/20
Fly Intel: Top five analyst initiations
02/19/20 Mizuho
Mizuho starts BridgeBio with Buy rating, $51 price target
02/18/20 Mizuho
BridgeBio initiated with a Buy at Mizuho
01/07/20 Raymond James
BridgeBio price target raised to $40 from $36 at Raymond James
CYAD Celyad
$9.78 /

-0.17 (-1.71%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
DCPH Deciphera
$54.35 /

+0.495 (+0.92%)

02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
02/20/20 Piper Sandler
Deciphera 20% selloff brings 'great entry point,' says Piper Sandler
01/24/20 SVB Leerink
Blueprint Medicines' Ayvakit added to NCCN guidelines, says SVB Leerink
01/22/20 Piper Sandler
Piper Sandler says 'incrementally positive' on Deciphera
FULC Fulcrum Therapeutics
$18.50 /

+2.28 (+14.06%)

12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
08/12/19 BofA
Fulcrum Therapeutics initiated with a Buy at BofA/Merrill
GH Guardant Health
$81.52 /

+5.75 (+7.59%)

02/21/20
Fly Intel: Top five analyst initiations
02/21/20 Guggenheim
Guggenheim starts Guardant Health at Buy with addressable market seen expanding
02/21/20 Guggenheim
Guardant Health initiated with a Buy at Guggenheim
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
IMVT Immunovant
$14.87 /

+0.015 (+0.10%)

02/24/20
Fly Intel: Top five analyst initiations
02/24/20 SVB Leerink
Immunovant initiated with an Outperform at SVB Leerink
02/05/20
Fly Intel: Top five analyst initiations
02/05/20 Nomura Instinet
Immunovant initiated with a Buy at Nomura Instinet
INGN Inogen
$47.88 /

+5.92 (+14.11%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
LMAT LeMaitre
$29.53 /

-0.35 (-1.17%)

10/24/19 Lake Street
Lake Street upgrades LeMaitre to Buy, boosts target to $40 from $34
10/24/19 Lake Street
LeMaitre upgraded to Buy from Hold at Lake Street
10/24/19 First Analysis
LeMaitre downgraded to Outperform from Strong Buy at First Analysis
10/14/19 First Analysis
LeMaitre upgraded to Strong Buy from Outperform at First Analysis
NUAN Nuance
$22.27 /

+0.17 (+0.77%)

01/13/20 Morgan Stanley
Morgan Stanley upgrades Nuance to Overweight on path to double-digit EPS growth
01/13/20 Morgan Stanley
Nuance upgraded to Overweight from Equal Weight at Morgan Stanley
10/02/19 Evercore ISI
Cerence initiated with an Outperform at Evercore ISI
10/01/19 Raymond James
Cerence initiated with a Strong Buy at Raymond James
NVCN Neovasc
$2.70 /

+0.04 (+1.50%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
03/22/19 Canaccord
Neovasc court win in Germany removes overhang, says Canaccord
RARE Ultragenyx
$55.71 /

+0.88 (+1.60%)

01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
11/27/19 Cowen
Ultragenyx weakness a buying opportunity, says Cowen
QURE uniQure
$53.57 /

-0.96 (-1.76%)

01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
12/09/19 H.C. Wainwright
uniQure has 'best in class' hemophilia B profile, says H.C. Wainwright
SELB Selecta Biosciences
$4.21 /

+0.215 (+5.38%)

02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
02/18/20 Mizuho
Selecta Biosciences price target raised to $7 from $4 at Mizuho
01/29/20
Fly Intel: Top five analyst initiations
01/29/20 Cantor Fitzgerald
Cantor starts 'under the radar' Selecta Biosciences with Overweight rating
VCEL Vericel
$15.06 /

-1.645 (-9.85%)

10/09/19 H.C. Wainwright
Vericel initiated with a Buy rating at H.C. Wainwright
08/26/19 Credit Suisse
Organogenesis reinstated with an Outperform at Credit Suisse
08/14/19 Oppenheimer
MediWound price target lowered to $7 from $15 at Oppenheimer
05/07/19 Oppenheimer
Vericel price target raised to $32 from $23 at Oppenheimer
RDUS Radius Health
$17.87 /

-0.06 (-0.33%)

11/06/19 SVB Leerink
Radius Health price target lowered to $35 from $49 at SVB Leerink
08/29/19 Citi
Radius Health upgraded to Buy from Neutral at Citi
05/30/19 Citi
Radius Health assumed with a Neutral at Citi
05/29/19 Goldman Sachs
Radius Health upgraded to Buy from Neutral at Goldman Sachs
PODD Insulet
$180.00 /

-17.03 (-8.64%)

02/26/20 Cowen
Insulet weakness a buying opportunity, says Cowen
02/26/20 Raymond James
Insulet price target lowered to $205 from $213 at Raymond James
02/26/20 Piper Sandler
Insulet should be bought on selloff from guidance, says Piper Sandler
02/19/20 Piper Sandler
New partnerships expected, but positive, for Insulet, says Piper Sandler
RDHL RedHill Biopharma
$4.68 /

+0.12 (+2.63%)

07/12/19 WBB Securities
RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
03/12/19
Fly Intel: Top five analyst upgrades
03/12/19 WBB Securities
RedHill Biopharma upgraded to Buy from Hold at WBB Securities
02/27/19 H.C. Wainwright
RedHill Biopharma price target lowered to $16 from $36 at H.C. Wainwright
TCRR TCR2 Therapeutics
$13.67 /

+0.36 (+2.70%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
05/31/19 Roth Capital
TCR2 Therapeutics initiated with a Neutral at Roth Capital
03/11/19
Fly Intel: Top five analyst initiations
03/11/19 SVB Leerink
TCR2 Therapeutics initiated with an Outperform at SVB Leerink
ORGO Organogenesis
$4.23 /

-0.14 (-3.20%)

01/10/20 SVB Leerink
Organogenesis initiated with an Outperform at SVB Leerink
05/02/19 Credit Suisse
Organogenesis initiated with an Outperform at Credit Suisse
04/17/19
Fly Intel: Top five analyst initiations
OSMT Osmotica Pharmaceuticals
$5.45 /

+0.32 (+6.24%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
08/12/19 Jefferies
Osmotica shares discounting late-stage pipeline, says Jefferies
06/11/19 Barclays
Osmotica Pharmaceuticals transferred with an Overweight rating at Barclays
03/28/19 Wells Fargo
Wells Fargo cuts Osmotica target to $14 after 'disappointing' study results
MLND Millendo Therapeutics
$8.75 /

+0.08 (+0.92%)

01/10/20 Roth Capital
Millendo Therapeutics initiated with a Buy at Roth Capital
09/16/19 Jefferies
Millendo Therapeutics assumed with a Buy at Jefferies
07/19/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
07/18/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
ITCI Intra-Cellular
$22.24 /

-0.79 (-3.43%)

02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
02/18/20 Cantor Fitzgerald
Intra-Cellular price target raised to $47 from $43 at Cantor Fitzgerald
01/31/20 JPMorgan
Intra-Cellular downgraded to Neutral on high Caplyta expectations at JPMorgan
IFRX InflaRx
$4.84 /

+0.69 (+16.63%)

07/19/19 Raymond James
InflaRx should not proceed with IFX-1 in HS, says Raymond James
06/06/19 Raymond James
ChemoCentryx price target lowered to $17 from $24 at Raymond James
06/05/19
InflaRx downgraded to Market Perform on HS study results at Raymond James
06/05/19 Piper Sandler
Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure
STSA Satsuma Pharmaceuticals
$26.10 /

-0.22 (-0.84%)

02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
10/08/19 SVB Leerink
Satsuma Pharmaceuticals initiated with an Outperform at SVB Leerink
10/08/19 Credit Suisse
Satsuma Pharmaceuticals initiated with an Outperform at Credit Suisse
MIRM Mirum Pharmaceuticals
$16.53 /

-0.81 (-4.67%)

12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
08/12/19
Fly Intel: Top five analyst initiations
08/12/19 Raymond James
Mirum Pharmaceuticals initiated with an Outperform at Raymond James
Over a quarter ago
Conference/Events
SVB Leerink to hold a conference » 04:55
02/26/20
02/26
04:55
02/26/20
04:55
ABBV

AbbVie

$89.13 /

-4.01 (-4.31%)

, BBIO

BridgeBio

$31.95 /

-1.3 (-3.91%)

, CYAD

Celyad

$9.95 /

+ (+0.00%)

, DCPH

Deciphera

$53.86 /

+0.055 (+0.10%)

, FULC

Fulcrum Therapeutics

$16.22 /

-0.09 (-0.55%)

, GH

Guardant Health

$75.77 /

-8.32 (-9.89%)

, IMVT

Immunovant

$14.86 /

+0.055 (+0.37%)

, INGN

Inogen

$41.96 /

-1.54 (-3.54%)

, LMAT

LeMaitre

$29.88 /

-0.22 (-0.73%)

, NUAN

Nuance

$22.10 /

-0.73 (-3.20%)

, NVCN

Neovasc

$2.66 /

-0.21 (-7.32%)

, RARE

Ultragenyx

$54.83 /

-2.26 (-3.96%)

, QURE

uniQure

$54.53 /

-3.85 (-6.59%)

, SELB

Selecta Biosciences

$4.00 /

-0.225 (-5.33%)

, VCEL

Vericel

$16.71 /

-2.22 (-11.73%)

, RDUS

Radius Health

$17.93 /

-1.05 (-5.53%)

, PODD

Insulet

$197.03 /

-10.46 (-5.04%)

, RDHL

RedHill Biopharma

$4.56 /

-0.15 (-3.18%)

, TCRR

TCR2 Therapeutics

$13.31 /

-0.37 (-2.70%)

, ORGO

Organogenesis

$4.37 /

-0.13 (-2.89%)

, OSMT

Osmotica Pharmaceuticals

$5.13 /

-0.46 (-8.23%)

, MLND

Millendo Therapeutics

$8.67 /

-0.8 (-8.45%)

, ITCI

Intra-Cellular

$23.03 /

-0.02 (-0.09%)

, IFRX

InflaRx

$4.15 /

-0.1 (-2.35%)

, STSA

Satsuma Pharmaceuticals

$26.32 /

-0.22 (-0.83%)

, MIRM

Mirum Pharmaceuticals

$17.34 /

-1 (-5.45%)

9th Annual Global…

9th Annual Global Healthcare Conference will be held in New York on February 25-27.

ShowHide Related Items >><<
ABBV AbbVie
$89.13 /

-4.01 (-4.31%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
BBIO BridgeBio
$31.95 /

-1.3 (-3.91%)

02/19/20
Fly Intel: Top five analyst initiations
02/19/20 Mizuho
Mizuho starts BridgeBio with Buy rating, $51 price target
02/18/20 Mizuho
BridgeBio initiated with a Buy at Mizuho
01/07/20 Raymond James
BridgeBio price target raised to $40 from $36 at Raymond James
CYAD Celyad
$9.95 /

+ (+0.00%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
DCPH Deciphera
$53.86 /

+0.055 (+0.10%)

02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
02/20/20 Piper Sandler
Deciphera 20% selloff brings 'great entry point,' says Piper Sandler
01/24/20 SVB Leerink
Blueprint Medicines' Ayvakit added to NCCN guidelines, says SVB Leerink
01/22/20 Piper Sandler
Piper Sandler says 'incrementally positive' on Deciphera
FULC Fulcrum Therapeutics
$16.22 /

-0.09 (-0.55%)

12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
08/12/19 BofA
Fulcrum Therapeutics initiated with a Buy at BofA/Merrill
GH Guardant Health
$75.77 /

-8.32 (-9.89%)

02/21/20
Fly Intel: Top five analyst initiations
02/21/20 Guggenheim
Guggenheim starts Guardant Health at Buy with addressable market seen expanding
02/21/20 Guggenheim
Guardant Health initiated with a Buy at Guggenheim
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
IMVT Immunovant
$14.86 /

+0.055 (+0.37%)

02/24/20
Fly Intel: Top five analyst initiations
02/24/20 SVB Leerink
Immunovant initiated with an Outperform at SVB Leerink
02/05/20
Fly Intel: Top five analyst initiations
02/05/20 Nomura Instinet
Immunovant initiated with a Buy at Nomura Instinet
INGN Inogen
$41.96 /

-1.54 (-3.54%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
LMAT LeMaitre
$29.88 /

-0.22 (-0.73%)

10/24/19 Lake Street
Lake Street upgrades LeMaitre to Buy, boosts target to $40 from $34
10/24/19 Lake Street
LeMaitre upgraded to Buy from Hold at Lake Street
10/24/19 First Analysis
LeMaitre downgraded to Outperform from Strong Buy at First Analysis
10/14/19 First Analysis
LeMaitre upgraded to Strong Buy from Outperform at First Analysis
NUAN Nuance
$22.10 /

-0.73 (-3.20%)

01/13/20 Morgan Stanley
Morgan Stanley upgrades Nuance to Overweight on path to double-digit EPS growth
01/13/20 Morgan Stanley
Nuance upgraded to Overweight from Equal Weight at Morgan Stanley
10/02/19 Evercore ISI
Cerence initiated with an Outperform at Evercore ISI
10/01/19 Raymond James
Cerence initiated with a Strong Buy at Raymond James
NVCN Neovasc
$2.66 /

-0.21 (-7.32%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
03/22/19 Canaccord
Neovasc court win in Germany removes overhang, says Canaccord
RARE Ultragenyx
$54.83 /

-2.26 (-3.96%)

01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
11/27/19 Cowen
Ultragenyx weakness a buying opportunity, says Cowen
QURE uniQure
$54.53 /

-3.85 (-6.59%)

01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
12/09/19 H.C. Wainwright
uniQure has 'best in class' hemophilia B profile, says H.C. Wainwright
SELB Selecta Biosciences
$4.00 /

-0.225 (-5.33%)

02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
02/18/20 Mizuho
Selecta Biosciences price target raised to $7 from $4 at Mizuho
01/29/20
Fly Intel: Top five analyst initiations
01/29/20 Cantor Fitzgerald
Cantor starts 'under the radar' Selecta Biosciences with Overweight rating
VCEL Vericel
$16.71 /

-2.22 (-11.73%)

10/09/19 H.C. Wainwright
Vericel initiated with a Buy rating at H.C. Wainwright
08/26/19 Credit Suisse
Organogenesis reinstated with an Outperform at Credit Suisse
08/14/19 Oppenheimer
MediWound price target lowered to $7 from $15 at Oppenheimer
05/07/19 Oppenheimer
Vericel price target raised to $32 from $23 at Oppenheimer
RDUS Radius Health
$17.93 /

-1.05 (-5.53%)

11/06/19 SVB Leerink
Radius Health price target lowered to $35 from $49 at SVB Leerink
08/29/19 Citi
Radius Health upgraded to Buy from Neutral at Citi
05/30/19 Citi
Radius Health assumed with a Neutral at Citi
05/29/19 Goldman Sachs
Radius Health upgraded to Buy from Neutral at Goldman Sachs
PODD Insulet
$197.03 /

-10.46 (-5.04%)

02/19/20 Piper Sandler
New partnerships expected, but positive, for Insulet, says Piper Sandler
02/13/20 Piper Sandler
Insulet medical device correction will not impact growth, says Piper Sandler
02/06/20 Raymond James
Insulet price target raised to $213 from $158 at Raymond James
01/07/20 Cowen
Cowen sees minimal Q4 earnings risk for diabetes device stocks
RDHL RedHill Biopharma
$4.56 /

-0.15 (-3.18%)

07/12/19 WBB Securities
RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
03/12/19
Fly Intel: Top five analyst upgrades
03/12/19 WBB Securities
RedHill Biopharma upgraded to Buy from Hold at WBB Securities
02/27/19 H.C. Wainwright
RedHill Biopharma price target lowered to $16 from $36 at H.C. Wainwright
TCRR TCR2 Therapeutics
$13.31 /

-0.37 (-2.70%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
05/31/19 Roth Capital
TCR2 Therapeutics initiated with a Neutral at Roth Capital
03/11/19
Fly Intel: Top five analyst initiations
03/11/19 SVB Leerink
TCR2 Therapeutics initiated with an Outperform at SVB Leerink
ORGO Organogenesis
$4.37 /

-0.13 (-2.89%)

01/10/20 SVB Leerink
Organogenesis initiated with an Outperform at SVB Leerink
05/02/19 Credit Suisse
Organogenesis initiated with an Outperform at Credit Suisse
04/17/19
Fly Intel: Top five analyst initiations
OSMT Osmotica Pharmaceuticals
$5.13 /

-0.46 (-8.23%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
08/12/19 Jefferies
Osmotica shares discounting late-stage pipeline, says Jefferies
06/11/19 Barclays
Osmotica Pharmaceuticals transferred with an Overweight rating at Barclays
03/28/19 Wells Fargo
Wells Fargo cuts Osmotica target to $14 after 'disappointing' study results
MLND Millendo Therapeutics
$8.67 /

-0.8 (-8.45%)

01/10/20 Roth Capital
Millendo Therapeutics initiated with a Buy at Roth Capital
09/16/19 Jefferies
Millendo Therapeutics assumed with a Buy at Jefferies
07/19/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
07/18/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
ITCI Intra-Cellular
$23.03 /

-0.02 (-0.09%)

02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
02/18/20 Cantor Fitzgerald
Intra-Cellular price target raised to $47 from $43 at Cantor Fitzgerald
01/31/20 JPMorgan
Intra-Cellular downgraded to Neutral on high Caplyta expectations at JPMorgan
IFRX InflaRx
$4.15 /

-0.1 (-2.35%)

07/19/19 Raymond James
InflaRx should not proceed with IFX-1 in HS, says Raymond James
06/06/19 Raymond James
ChemoCentryx price target lowered to $17 from $24 at Raymond James
06/05/19
InflaRx downgraded to Market Perform on HS study results at Raymond James
06/05/19 Piper Sandler
Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure
STSA Satsuma Pharmaceuticals
$26.32 /

-0.22 (-0.83%)

02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
10/08/19 SVB Leerink
Satsuma Pharmaceuticals initiated with an Outperform at SVB Leerink
10/08/19 Credit Suisse
Satsuma Pharmaceuticals initiated with an Outperform at Credit Suisse
MIRM Mirum Pharmaceuticals
$17.34 /

-1 (-5.45%)

12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
08/12/19
Fly Intel: Top five analyst initiations
08/12/19 Raymond James
Mirum Pharmaceuticals initiated with an Outperform at Raymond James
Conference/Events
SVB Leerink to hold a conference » 07:58
02/25/20
02/25
07:58
02/25/20
07:58
ABBV

AbbVie

$93.14 /

-1.82 (-1.92%)

, BBIO

BridgeBio

$33.25 /

-2.84 (-7.87%)

, CYAD

Celyad

$9.95 /

-0.41 (-3.96%)

, DCPH

Deciphera

$53.80 /

-1.25 (-2.27%)

, FULC

Fulcrum Therapeutics

$16.31 /

-3.01 (-15.58%)

, GH

Guardant Health

$84.09 /

-4.85 (-5.45%)

, IMVT

Immunovant

$14.80 /

-0.71 (-4.58%)

, INGN

Inogen

$43.50 /

-0.64 (-1.45%)

, LMAT

LeMaitre

$30.10 /

-0.27 (-0.89%)

, NUAN

Nuance

$22.83 /

-0.37 (-1.59%)

, NVCN

Neovasc

$2.87 /

-0.16 (-5.28%)

, RARE

Ultragenyx

$57.09 /

-2.3 (-3.87%)

, QURE

uniQure

$58.38 /

-2.52 (-4.14%)

, SELB

Selecta Biosciences

$4.22 /

-0.02 (-0.47%)

, VCEL

Vericel

$18.93 /

-0.315 (-1.64%)

, RDUS

Radius Health

$18.98 /

-0.37 (-1.91%)

, PODD

Insulet

$207.49 /

-4.82 (-2.27%)

, RDHL

RedHill Biopharma

$4.71 /

-0.18 (-3.68%)

, TCRR

TCR2 Therapeutics

$13.68 /

-0.32 (-2.29%)

, ORGO

Organogenesis

$4.50 /

-0.35 (-7.22%)

, OSMT

Osmotica Pharmaceuticals

$5.59 /

-0.24 (-4.12%)

, MLND

Millendo Therapeutics

$9.47 /

+0.5 (+5.57%)

, ITCI

Intra-Cellular

$23.05 /

-1.63 (-6.60%)

, IFRX

InflaRx

$4.25 /

-0.31 (-6.80%)

, STSA

Satsuma Pharmaceuticals

$26.54 /

-2.21 (-7.69%)

, MIRM

Mirum Pharmaceuticals

$18.34 /

+1.61 (+9.62%)

9th Annual Global…

9th Annual Global Healthcare Conference will be held in New York on February 25-27.

ShowHide Related Items >><<
ABBV AbbVie
$93.14 /

-1.82 (-1.92%)

02/18/20 Cowen
AbbVie price target raised to $105 from $98 at Cowen
02/14/20 Piper Sandler
Piper says Ubrelvy prescription trajectory bodes well for Biohaven's rimegepant
02/11/20 SunTrust
Allergan price target raised to $202 from $194 at SunTrust
02/10/20 Mizuho
AbbVie price target raised to $104 from $96 at Mizuho
BBIO BridgeBio
$33.25 /

-2.84 (-7.87%)

02/19/20
Fly Intel: Top five analyst initiations
02/19/20 Mizuho
Mizuho starts BridgeBio with Buy rating, $51 price target
02/18/20 Mizuho
BridgeBio initiated with a Buy at Mizuho
01/07/20 Raymond James
BridgeBio price target raised to $40 from $36 at Raymond James
CYAD Celyad
$9.95 /

-0.41 (-3.96%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
DCPH Deciphera
$53.80 /

-1.25 (-2.27%)

02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
02/20/20 Piper Sandler
Deciphera 20% selloff brings 'great entry point,' says Piper Sandler
01/24/20 SVB Leerink
Blueprint Medicines' Ayvakit added to NCCN guidelines, says SVB Leerink
01/22/20 Piper Sandler
Piper Sandler says 'incrementally positive' on Deciphera
FULC Fulcrum Therapeutics
$16.31 /

-3.01 (-15.58%)

12/24/19 H.C. Wainwright
Fulcrum 2020 data may support accelerated approval, says H.C. Wainwright
10/03/19 H.C. Wainwright
Fulcrum Therapeutics initiated with a Buy at H.C. Wainwright
08/12/19 Morgan Stanley
Fulcrum Therapeutics initiated with an Overweight at Morgan Stanley
08/12/19 BofA
Fulcrum Therapeutics initiated with a Buy at BofA/Merrill
GH Guardant Health
$84.09 /

-4.85 (-5.45%)

02/21/20
Fly Intel: Top five analyst initiations
02/21/20 Guggenheim
Guggenheim starts Guardant Health at Buy with addressable market seen expanding
02/21/20 Guggenheim
Guardant Health initiated with a Buy at Guggenheim
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
IMVT Immunovant
$14.80 /

-0.71 (-4.58%)

02/24/20
Fly Intel: Top five analyst initiations
02/24/20 SVB Leerink
Immunovant initiated with an Outperform at SVB Leerink
02/05/20
Fly Intel: Top five analyst initiations
02/05/20 Nomura Instinet
Immunovant initiated with a Buy at Nomura Instinet
INGN Inogen
$43.50 /

-0.64 (-1.45%)

01/13/20 William Blair
Inogen's softer than expected DTC demand a surprise, says William Blair
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
11/06/19 Needham
Inogen upgraded to Buy from Hold at Needham
09/12/19 Piper Sandler
Piper confident in Inogen's double-digit growth potential for 2020
LMAT LeMaitre
$30.10 /

-0.27 (-0.89%)

10/24/19 Lake Street
Lake Street upgrades LeMaitre to Buy, boosts target to $40 from $34
10/24/19 Lake Street
LeMaitre upgraded to Buy from Hold at Lake Street
10/24/19 First Analysis
LeMaitre downgraded to Outperform from Strong Buy at First Analysis
10/14/19 First Analysis
LeMaitre upgraded to Strong Buy from Outperform at First Analysis
NUAN Nuance
$22.83 /

-0.37 (-1.59%)

01/13/20 Morgan Stanley
Morgan Stanley upgrades Nuance to Overweight on path to double-digit EPS growth
01/13/20 Morgan Stanley
Nuance upgraded to Overweight from Equal Weight at Morgan Stanley
10/02/19 Evercore ISI
Cerence initiated with an Outperform at Evercore ISI
10/01/19 Raymond James
Cerence initiated with a Strong Buy at Raymond James
NVCN Neovasc
$2.87 /

-0.16 (-5.28%)

10/24/19 H.C. Wainwright
Neovasc initiated with a Buy at H.C. Wainwright
03/22/19 Canaccord
Neovasc court win in Germany removes overhang, says Canaccord
RARE Ultragenyx
$57.09 /

-2.3 (-3.87%)

01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
11/27/19 Cowen
Ultragenyx weakness a buying opportunity, says Cowen
QURE uniQure
$58.38 /

-2.52 (-4.14%)

01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
12/09/19 H.C. Wainwright
uniQure has 'best in class' hemophilia B profile, says H.C. Wainwright
SELB Selecta Biosciences
$4.22 /

-0.02 (-0.47%)

02/21/20 Cantor Fitzgerald
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald
02/18/20 Mizuho
Selecta Biosciences price target raised to $7 from $4 at Mizuho
01/29/20
Fly Intel: Top five analyst initiations
01/29/20 Cantor Fitzgerald
Cantor starts 'under the radar' Selecta Biosciences with Overweight rating
VCEL Vericel
$18.93 /

-0.315 (-1.64%)

10/09/19 H.C. Wainwright
Vericel initiated with a Buy rating at H.C. Wainwright
08/26/19 Credit Suisse
Organogenesis reinstated with an Outperform at Credit Suisse
08/14/19 Oppenheimer
MediWound price target lowered to $7 from $15 at Oppenheimer
05/07/19 Oppenheimer
Vericel price target raised to $32 from $23 at Oppenheimer
RDUS Radius Health
$18.98 /

-0.37 (-1.91%)

11/06/19 SVB Leerink
Radius Health price target lowered to $35 from $49 at SVB Leerink
08/29/19 Citi
Radius Health upgraded to Buy from Neutral at Citi
05/30/19 Citi
Radius Health assumed with a Neutral at Citi
05/29/19 Goldman Sachs
Radius Health upgraded to Buy from Neutral at Goldman Sachs
PODD Insulet
$207.49 /

-4.82 (-2.27%)

02/19/20 Piper Sandler
New partnerships expected, but positive, for Insulet, says Piper Sandler
02/13/20 Piper Sandler
Insulet medical device correction will not impact growth, says Piper Sandler
02/06/20 Raymond James
Insulet price target raised to $213 from $158 at Raymond James
01/07/20 Cowen
Cowen sees minimal Q4 earnings risk for diabetes device stocks
RDHL RedHill Biopharma
$4.71 /

-0.18 (-3.68%)

07/12/19 WBB Securities
RedHill Biopharma upgraded to Strong Buy from Buy at WBB Securities
03/12/19
Fly Intel: Top five analyst upgrades
03/12/19 WBB Securities
RedHill Biopharma upgraded to Buy from Hold at WBB Securities
02/27/19 H.C. Wainwright
RedHill Biopharma price target lowered to $16 from $36 at H.C. Wainwright
TCRR TCR2 Therapeutics
$13.68 /

-0.32 (-2.29%)

11/04/19 H.C. Wainwright
TCR2 Therapeutics initiated with a Buy at H.C. Wainwright
05/31/19 Roth Capital
TCR2 Therapeutics initiated with a Neutral at Roth Capital
03/11/19
Fly Intel: Top five analyst initiations
03/11/19 SVB Leerink
TCR2 Therapeutics initiated with an Outperform at SVB Leerink
ORGO Organogenesis
$4.50 /

-0.35 (-7.22%)

01/10/20 SVB Leerink
Organogenesis initiated with an Outperform at SVB Leerink
05/02/19 Credit Suisse
Organogenesis initiated with an Outperform at Credit Suisse
04/17/19
Fly Intel: Top five analyst initiations
OSMT Osmotica Pharmaceuticals
$5.59 /

-0.24 (-4.12%)

01/22/20 Wells Fargo
Revance, Amphastar named top 2020 Specialty Pharmaceuticals ideas at Wells Fargo
08/12/19 Jefferies
Osmotica shares discounting late-stage pipeline, says Jefferies
06/11/19 Barclays
Osmotica Pharmaceuticals transferred with an Overweight rating at Barclays
03/28/19 Wells Fargo
Wells Fargo cuts Osmotica target to $14 after 'disappointing' study results
MLND Millendo Therapeutics
$9.47 /

+0.5 (+5.57%)

01/10/20 Roth Capital
Millendo Therapeutics initiated with a Buy at Roth Capital
09/16/19 Jefferies
Millendo Therapeutics assumed with a Buy at Jefferies
07/19/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
07/18/19 Wedbush
Millendo Therapeutics initiated with an Outperform at Wedbush
ITCI Intra-Cellular
$23.05 /

-1.63 (-6.60%)

02/20/20
Fly Intel: Top five analyst initiations
02/19/20 Evercore ISI
Intra-Cellular initiated with an Outperform at Evercore ISI
02/18/20 Cantor Fitzgerald
Intra-Cellular price target raised to $47 from $43 at Cantor Fitzgerald
01/31/20 JPMorgan
Intra-Cellular downgraded to Neutral on high Caplyta expectations at JPMorgan
IFRX InflaRx
$4.25 /

-0.31 (-6.80%)

07/19/19 Raymond James
InflaRx should not proceed with IFX-1 in HS, says Raymond James
06/06/19 Raymond James
ChemoCentryx price target lowered to $17 from $24 at Raymond James
06/05/19
InflaRx downgraded to Market Perform on HS study results at Raymond James
06/05/19 Piper Sandler
Piper Jaffray cuts ChemoCentryx target to $17 after InflaRx failure
STSA Satsuma Pharmaceuticals
$26.54 /

-2.21 (-7.69%)

02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
02/05/20 Mizuho
Satsuma Pharmaceuticals initiated with a Buy at Mizuho
10/08/19 SVB Leerink
Satsuma Pharmaceuticals initiated with an Outperform at SVB Leerink
10/08/19 Credit Suisse
Satsuma Pharmaceuticals initiated with an Outperform at Credit Suisse
MIRM Mirum Pharmaceuticals
$18.34 /

+1.61 (+9.62%)

12/17/19 Citi
Mirum Pharmaceuticals price target raised to $30 from $21 at Citi
12/16/19 Roth Capital
Mirum update shortens development timeframe by two years, says Roth Capital
08/12/19
Fly Intel: Top five analyst initiations
08/12/19 Raymond James
Mirum Pharmaceuticals initiated with an Outperform at Raymond James
Hot Stocks
Celyad doses first patient with CYAD-02 in Phase 1 CYCLE-1 trial » 05:11
01/13/20
01/13
05:11
01/13/20
05:11
CYAD

Celyad

$11.20 /

+0.79 (+7.59%)

Celyad announced the…

Celyad announced the successful administration of the next-generation, NKG2D-based candidate CYAD-02 to a relapsed/refractory acute myeloid leukemia patient enrolled in the Phase 1 CYCLE-1 trial.

ShowHide Related Items >><<
CYAD Celyad
$11.20 /

+0.79 (+7.59%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
Conference/Events
Evercore ISI to hold a conference » 04:55
12/05/19
12/05
04:55
12/05/19
04:55
MTEM

Molecular Templates

$12.73 /

+0.81 (+6.80%)

, ALNA

Allena Pharmaceuticals

$2.31 /

+0.01 (+0.43%)

, MDGL

Madrigal Pharmaceuticals

$116.14 /

+2.44 (+2.15%)

, PHG

Philips

$46.39 /

+0.35 (+0.76%)

, QURE

uniQure

$65.39 /

+1.52 (+2.38%)

, MBIO

Mustang Bio

$3.89 /

+0.5 (+14.75%)

, SEEL

Seelos Therapeutics

$0.95 /

+0.0863 (+10.03%)

, CYAD

Celyad

$12.71 /

+0.56 (+4.61%)

, PFNX

Pfenex

$10.86 /

+0.34 (+3.23%)

, STRO

Sutro Biopharma

$11.00 /

-0.16 (-1.43%)

, AXNX

Axonics

$24.13 /

+0.56 (+2.38%)

, NBSE

NeuBase Therapeutics

$6.93 /

+0.05 (+0.73%)

, ZBH

Zimmer Biomet

$148.35 /

+4.93 (+3.44%)

, ALIM

Alimera Sciences

$7.16 /

+0.41 (+6.07%)

, INSM

Insmed

$23.36 /

+0.4 (+1.74%)

, ADMS

Adamas Pharmaceuticals

$6.40 /

-0.12 (-1.84%)

, AXGT

Axovant

$5.20 /

+0.08 (+1.56%)

, BCEL

Atreca

$13.00 /

-0.285 (-2.15%)

, MYOV

Myovant Sciences

$17.30 /

-1.26 (-6.79%)

, PIRS

Pieris Pharmaceuticals

$3.93 /

+0.03 (+0.77%)

, MYL

Mylan

$18.89 /

+0.365 (+1.97%)

, RCKT

Rocket Pharmaceuticals

$19.22 /

+0.88 (+4.80%)

, CBAY

CymaBay

$1.66 /

-0.01 (-0.60%)

, NBIX

Neurocrine

$118.67 /

+1.08 (+0.92%)

, TCDA

Tricida

$39.62 /

+0.09 (+0.23%)

, NTLA

Intellia Therapeutics

$17.67 /

+0.59 (+3.45%)

, ALKS

Alkermes

$21.24 /

+0.98 (+4.84%)

HealthCONx Conference…

HealthCONx Conference 2019 will be held in Boston on December 3-5.

ShowHide Related Items >><<
MTEM Molecular Templates
$12.73 /

+0.81 (+6.80%)

04/29/19 UBS
Molecular Templates initiated with a Buy at UBS
12/10/18 Oppenheimer
Molecular Templates initiated with an Outperform at Oppenheimer
ALNA Allena Pharmaceuticals
$2.31 /

+0.01 (+0.43%)

11/08/19 B. Riley FBR
Allena Pharmaceuticals selloff yesterday overdone, says B. Riley FBR
11/07/19 Roth Capital
Allena's high placebo result in URIROX-1 a 'red herring,' says Roth Capital
11/07/19 Baird
Allena Pharmaceuticals selloff today a buying opportunity, says Baird
09/06/19 Credit Suisse
Allena Pharmaceuticals price target lowered to $7 from $26 at Credit Suisse
MDGL Madrigal Pharmaceuticals
$116.14 /

+2.44 (+2.15%)

12/02/19 Citi
Madrigal Pharmaceuticals price target lowered to $166 from $173 at Citi
09/17/19 Citi
Madrigal Pharmaceuticals price target lowered to $173 from $186 at Citi
06/25/19 Stifel
Madrigal Pharmaceuticals initiated with a Hold at Stifel
06/10/19 B. Riley FBR
Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley FBR
PHG Philips
$46.39 /

+0.35 (+0.76%)

07/30/19
Fly Intel: Top five analyst initiations
07/30/19 Citi
Philips initiated with a Buy at Citi
04/16/19 BTIG
Masimo downgraded to Neutral from Buy at BTIG
QURE uniQure
$65.39 /

+1.52 (+2.38%)

12/03/19 Piper Sandler
uniQure a name 'investors need to own,' says Piper Jaffray
12/03/19
Fly Intel: Top five analyst initiations
12/03/19 Cowen
uniQure initiated with an Outperform at Cowen
12/03/19 Goldman Sachs
uniQure initiated with a Buy at Goldman Sachs
MBIO Mustang Bio
$3.89 /

+0.5 (+14.75%)

11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
06/21/19 Cantor Fitzgerald
Cantor starts Mustang Bio with Overweight rating, $7 price target
06/20/19 Cantor Fitzgerald
Mustang Bio initiated with an Overweight at Cantor Fitzgerald
SEEL Seelos Therapeutics
$0.95 /

+0.0863 (+10.03%)

11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
11/14/19 Benchmark
Seelos Therapeutics initiated with a Speculative Buy at Benchmark
05/14/19 Roth Capital
Seelos Therapeutics initiated with a Buy at Roth Capital
05/10/19 H.C. Wainwright
Seelos Therapeutics initiated with a Buy at H.C. Wainwright
CYAD Celyad
$12.71 /

+0.56 (+4.61%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
PFNX Pfenex
$10.86 /

+0.34 (+3.23%)

10/25/19 Cantor Fitzgerald
Cantor starts Pfenex at Overweight, sees 'significant value' despite run
10/24/19 Cantor Fitzgerald
Pfenex initiated with an Overweight at Cantor Fitzgerald
09/11/19 JMP Securities
Pfenex price target raised to $17 from $13 at JMP Securities
04/02/19 Wells Fargo
BARDA passing on Pfenex good news for Emergent, says Wells Fargo
STRO Sutro Biopharma
$11.00 /

-0.16 (-1.43%)

10/07/19
Fly Intel: Top five analyst initiations
10/07/19 BTIG
Sutro Biopharma initiated with a Buy at BTIG
09/05/19 JMP Securities
Sutro Biopharma resumed with an Outperform at JMP Securities
07/18/19 Deutsche Bank
Sutro Biopharma initiated with a Buy at Deutsche Bank
AXNX Axonics
$24.13 /

+0.56 (+2.38%)

11/05/19 Piper Sandler
Medtronic filed patent lawsuit against Axonics, says Piper Jaffray
11/04/19 Piper Sandler
Axonics doctor checks suggest 'meaningful share capture,' says Piper Jaffray
11/01/19 Piper Sandler
Axonics initiated with an Overweight at Piper Jaffray
10/21/19 Barclays
Axonics initiated with an Overweight at Barclays
NBSE NeuBase Therapeutics
$6.93 /

+0.05 (+0.73%)

11/20/19 Oppenheimer
NeuBase Therapeutics initiated with an Outperform at Oppenheimer
10/29/19 H.C. Wainwright
NeuBase Therapeutics initiated with a Buy at H.C. Wainwright
09/24/19 BTIG
NeuBase Therapeutics initiated with a Buy at BTIG
ZBH Zimmer Biomet
$148.35 /

+4.93 (+3.44%)

12/04/19 Raymond James
Zimmer Biomet upgraded to Strong Buy at Raymond James, PT raised to $170
12/04/19 Raymond James
Zimmer Biomet upgraded to Strong Buy from Outperform at Raymond James
11/06/19 Raymond James
Zimmer Biomet price target raised to $160 from $150 at Raymond James
11/06/19 SVB Leerink
Zimmer Biomet price target raised to $160 from $155 at SVB Leerink
ALIM Alimera Sciences
$7.16 /

+0.41 (+6.07%)

09/30/19 B. Riley FBR
Alimera checks show 'substantial' recovery in Q3, says B. Riley FBR
05/28/19 Craig-Hallum
Alimera Sciences initiated with a Buy at Craig-Hallum
INSM Insmed
$23.36 /

+0.4 (+1.74%)

09/03/19 Goldman Sachs
Insmed initiated with a Buy at Goldman Sachs
08/01/19 Stifel
Insmed selloff 'decidedly overdone,' says Stifel
04/09/19 H.C. Wainwright
Insmed price target raised to $52 from $43 at H.C. Wainwright
03/26/19 Stifel
Pulmonologist call reinforces Stifel view of upside for Insmed
ADMS Adamas Pharmaceuticals
$6.40 /

-0.12 (-1.84%)

11/08/19 JMP Securities
Adamas Pharmaceuticals price target lowered to $16 from $57 at JMP Securities
09/30/19 BofA
Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill
09/30/19 BofA
Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill
09/09/19
Fly Intel: Top five analyst initiations
AXGT Axovant
$5.20 /

+0.08 (+1.56%)

08/12/19 Baird
Axovant upgraded to Outperform at Baird
08/12/19 Baird
Axovant upgraded to Outperform from Neutral at Baird
06/21/19 SVB Leerink
Axovant initiated with an Outperform at SVB Leerink
06/06/19 JMP Securities
Axovant price target raised to $28 after reverse split at JMP Securities
BCEL Atreca
$13.00 /

-0.285 (-2.15%)

09/04/19 Roth Capital
Atreca initiated with a Buy at Roth Capital
07/15/19
Fly Intel: Top five analyst initiations
07/15/19 Cowen
Atreca initiated with an Outperform at Cowen
07/15/19 Canaccord
Atreca initiated with a Buy at Canaccord
MYOV Myovant Sciences
$17.30 /

-1.26 (-6.79%)

11/19/19 Goldman Sachs
Myovant Sciences price target raised to $20 from $18 at Goldman Sachs
11/19/19 JMP Securities
JMP boosts Myovant price target to $34 after 'compelling' prostate cancer data
08/28/19
Fly Intel: Top five analyst initiations
08/28/19 Goldman Sachs
Slower Orilissa ramp has minimal impact on Neurocrine, says Goldman Sachs
PIRS Pieris Pharmaceuticals
$3.93 /

+0.03 (+0.77%)

07/30/19 Baird
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
07/29/19 William Blair
Updates 'very positive' for upcoming Pieris presentation, says William Blair
05/14/19 Baird
Pieris Pharmaceuticals initiated with an Outperform at Baird
05/13/19 Baird
Pieris Pharmaceuticals initiated with an Outperform at Baird
MYL Mylan
$18.89 /

+0.365 (+1.97%)

11/19/19 Morgan Stanley
Mylan only IPR challenger remaining for Biogen's Tecfidera, says Morgan Stanley
11/07/19
Fly Intel: Top five analyst downgrades
11/07/19 Morgan Stanley
Mylan downgraded to Equal Weight on growth uncertainty at Morgan Stanley
11/07/19 Morgan Stanley
Mylan downgraded to Equal Weight from Overweight at Morgan Stanley
RCKT Rocket Pharmaceuticals
$19.22 /

+0.88 (+4.80%)

11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray
11/07/19 Piper Sandler
Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray
11/05/19 Chardan
Rocket Pharmaceuticals initiated with a Buy at Chardan
10/24/19 Piper Sandler
Rocket Pharmaceuticals data update 'incrementally positive,' says Piper Jaffray
CBAY CymaBay
$1.66 /

-0.01 (-0.60%)

11/26/19 H.C. Wainwright
Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright
11/26/19
Fly Intel: Top five analyst downgrades
11/26/19 Roth Capital
CymaBay downgraded to Neutral from Buy at Roth Capital
11/26/19 Raymond James
CymaBay double downgraded at Raymond James after seladelpar setback
NBIX Neurocrine
$118.67 /

+1.08 (+0.92%)

11/05/19 Piper Sandler
Neurocrine price target raised to $116 from $111 at Piper Jaffray
10/04/19 Guggenheim
Guggenheim positively biased on Biotech heading into earnings
09/25/19 RBC Capital
Neurocrine approval in Huntington's could add upside, says RBC Capital
TCDA Tricida
$39.62 /

+0.09 (+0.23%)

06/27/19 Goldman Sachs
Goldman starts 'potential game-changer' Tricida with Buy, $48 price target
06/26/19 Goldman Sachs
Tricida initiated with a Buy at Goldman Sachs
05/24/19 Needham
Tricida initiated with a Buy at Needham
04/01/19 Empire
Tricida price target raised to $58 from $37 at Empire
NTLA Intellia Therapeutics
$17.67 /

+0.59 (+3.45%)

12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James
11/01/19 Raymond James
Intellia Therapeutics upgraded to Outperform at Raymond James
11/01/19 Raymond James
Intellia upgraded to Outperform from Market Perform at Raymond James
07/09/19
Fly Intel: Top five analyst initiations
ALKS Alkermes
$21.24 /

+0.98 (+4.84%)

11/18/19 Piper Sandler
Alkermes deal strengthens early-stage pipeline, says Piper Jaffray
11/18/19 Stifel
Alkermes made 'nice strategic move' in buying Rodin, says Stifel
11/11/19 Morgan Stanley
Alkermes data at SITC too early to assess 4230 potential, says Morgan Stanley
11/01/19 H.C. Wainwright
Alkermes price target lowered to $26 from $28 at H.C. Wainwright
Conference/Events
Evercore ISI to hold a conference » 04:55
12/04/19
12/04
04:55
12/04/19
04:55
MTEM

Molecular Templates

$11.92 /

+0.24 (+2.05%)

, ALNA

Allena Pharmaceuticals

$2.30 /

-0.12 (-4.96%)

, MDGL

Madrigal Pharmaceuticals

$113.70 /

-0.66 (-0.58%)

, PHG

Philips

$46.04 /

+0.14 (+0.31%)

, QURE

uniQure

$63.87 /

+9.06 (+16.53%)

, MBIO

Mustang Bio

$3.39 /

+0.12 (+3.67%)

, SEEL

Seelos Therapeutics

$0.86 /

-0.041 (-4.55%)

, CYAD

Celyad

$12.15 /

+0.55 (+4.74%)

, PFNX

Pfenex

$10.52 /

+0.525 (+5.25%)

, STRO

Sutro Biopharma

$11.16 /

-0.09 (-0.80%)

, AXNX

Axonics

$23.57 /

+0.36 (+1.55%)

, NBSE

NeuBase Therapeutics

$6.88 /

-0.48 (-6.52%)

, ZBH

Zimmer Biomet

$143.42 /

-1.05 (-0.73%)

, ALIM

Alimera Sciences

$6.75 /

-0.02 (-0.30%)

, INSM

Insmed

$22.96 /

-0.11 (-0.48%)

, ADMS

Adamas Pharmaceuticals

$6.52 /

+0.37 (+6.02%)

, AXGT

Axovant

$5.12 /

-0.19 (-3.58%)

, BCEL

Atreca

$13.29 /

+3.185 (+31.53%)

, MYOV

Myovant Sciences

$18.56 /

-0.62 (-3.23%)

, PIRS

Pieris Pharmaceuticals

$3.90 /

-0.24 (-5.80%)

, MYL

Mylan

$18.53 /

-0.145 (-0.78%)

, RCKT

Rocket Pharmaceuticals

$18.34 /

+0.38 (+2.12%)

, CBAY

CymaBay

$1.67 /

+0.05 (+3.09%)

, NBIX

Neurocrine

$117.59 /

+0.77 (+0.66%)

, TCDA

Tricida

$39.53 /

-0.5 (-1.25%)

, NTLA

Intellia Therapeutics

$17.08 /

+0.03 (+0.18%)

, ALKS

Alkermes

$20.26 /

-0.29 (-1.41%)

HealthCONx Conference…

HealthCONx Conference 2019 will be held in Boston on December 3-5.

ShowHide Related Items >><<
MTEM Molecular Templates
$11.92 /

+0.24 (+2.05%)

04/29/19 UBS
Molecular Templates initiated with a Buy at UBS
12/10/18 Oppenheimer
Molecular Templates initiated with an Outperform at Oppenheimer
ALNA Allena Pharmaceuticals
$2.30 /

-0.12 (-4.96%)

11/08/19 B. Riley FBR
Allena Pharmaceuticals selloff yesterday overdone, says B. Riley FBR
11/07/19 Roth Capital
Allena's high placebo result in URIROX-1 a 'red herring,' says Roth Capital
11/07/19 Baird
Allena Pharmaceuticals selloff today a buying opportunity, says Baird
09/06/19 Credit Suisse
Allena Pharmaceuticals price target lowered to $7 from $26 at Credit Suisse
MDGL Madrigal Pharmaceuticals
$113.70 /

-0.66 (-0.58%)

12/02/19 Citi
Madrigal Pharmaceuticals price target lowered to $166 from $173 at Citi
09/17/19 Citi
Madrigal Pharmaceuticals price target lowered to $173 from $186 at Citi
06/25/19 Stifel
Madrigal Pharmaceuticals initiated with a Hold at Stifel
06/10/19 B. Riley FBR
Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley FBR
PHG Philips
$46.04 /

+0.14 (+0.31%)

07/30/19
Fly Intel: Top five analyst initiations
07/30/19 Citi
Philips initiated with a Buy at Citi
04/16/19 BTIG
Masimo downgraded to Neutral from Buy at BTIG
QURE uniQure
$63.87 /

+9.06 (+16.53%)

12/03/19 Piper Sandler
uniQure a name 'investors need to own,' says Piper Jaffray
12/03/19
Fly Intel: Top five analyst initiations
12/03/19 Cowen
uniQure initiated with an Outperform at Cowen
12/03/19 Goldman Sachs
uniQure initiated with a Buy at Goldman Sachs
MBIO Mustang Bio
$3.39 /

+0.12 (+3.67%)

11/20/19 Cantor Fitzgerald
Mustang Bio assumed with an Overweight at Cantor Fitzgerald
08/13/19 H.C. Wainwright
Mustang Bio initiated with a Buy at H.C. Wainwright
06/21/19 Cantor Fitzgerald
Cantor starts Mustang Bio with Overweight rating, $7 price target
06/20/19 Cantor Fitzgerald
Mustang Bio initiated with an Overweight at Cantor Fitzgerald
SEEL Seelos Therapeutics
$0.86 /

-0.041 (-4.55%)

11/18/19 H.C. Wainwright
Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
11/14/19 Benchmark
Seelos Therapeutics initiated with a Speculative Buy at Benchmark
05/14/19 Roth Capital
Seelos Therapeutics initiated with a Buy at Roth Capital
05/10/19 H.C. Wainwright
Seelos Therapeutics initiated with a Buy at H.C. Wainwright
CYAD Celyad
$12.15 /

+0.55 (+4.74%)

07/05/19 H.C. Wainwright
Celyad target lowered to $48 on new launch timeline at H.C. Wainwright
07/05/19 Piper Sandler
Celyad price target lowered to $25 from $41 at Piper Jaffray
06/17/19 SunTrust
Celyad selloff a buying opportunity, says SunTrust
06/17/19 Piper Sandler
Piper Jaffray reiterates Overweight on Celyad after EHA update
PFNX Pfenex
$10.52 /

+0.525 (+5.25%)

10/25/19 Cantor Fitzgerald
Cantor starts Pfenex at Overweight, sees 'significant value' despite run
10/24/19 Cantor Fitzgerald
Pfenex initiated with an Overweight at Cantor Fitzgerald
09/11/19 JMP Securities
Pfenex price target raised to $17 from $13 at JMP Securities
04/02/19 Wells Fargo
BARDA passing on Pfenex good news for Emergent, says Wells Fargo
STRO Sutro Biopharma
$11.16 /

-0.09 (-0.80%)

10/07/19
Fly Intel: Top five analyst initiations
10/07/19 BTIG
Sutro Biopharma initiated with a Buy at BTIG
09/05/19 JMP Securities
Sutro Biopharma resumed with an Outperform at JMP Securities
07/18/19 Deutsche Bank
Sutro Biopharma initiated with a Buy at Deutsche Bank
AXNX Axonics
$23.57 /

+0.36 (+1.55%)

11/05/19 Piper Sandler
Medtronic filed patent lawsuit against Axonics, says Piper Jaffray
11/04/19 Piper Sandler
Axonics doctor checks suggest 'meaningful share capture,' says Piper Jaffray
11/01/19 Piper Sandler
Axonics initiated with an Overweight at Piper Jaffray
10/21/19 Barclays
Axonics initiated with an Overweight at Barclays
NBSE NeuBase Therapeutics
$6.88 /

-0.48 (-6.52%)

11/20/19 Oppenheimer
NeuBase Therapeutics initiated with an Outperform at Oppenheimer
10/29/19 H.C. Wainwright
NeuBase Therapeutics initiated with a Buy at H.C. Wainwright
09/24/19 BTIG
NeuBase Therapeutics initiated with a Buy at BTIG
ZBH Zimmer Biomet
$143.42 /

-1.05 (-0.73%)

12/04/19 Raymond James
Zimmer Biomet upgraded to Strong Buy from Outperform at Raymond James
11/06/19 Raymond James
Zimmer Biomet price target raised to $160 from $150 at Raymond James
11/06/19 SVB Leerink
Zimmer Biomet price target raised to $160 from $155 at SVB Leerink
11/06/19 RBC Capital
Zimmer Biomet price target raised to $155 from $145 at RBC Capital
ALIM Alimera Sciences
$6.75 /

-0.02 (-0.30%)

09/30/19 B. Riley FBR
Alimera checks show 'substantial' recovery in Q3, says B. Riley FBR
05/28/19 Craig-Hallum
Alimera Sciences initiated with a Buy at Craig-Hallum
INSM Insmed
$22.96 /

-0.11 (-0.48%)

09/03/19 Goldman Sachs
Insmed initiated with a Buy at Goldman Sachs
08/01/19 Stifel
Insmed selloff 'decidedly overdone,' says Stifel
04/09/19 H.C. Wainwright
Insmed price target raised to $52 from $43 at H.C. Wainwright
03/26/19 Stifel
Pulmonologist call reinforces Stifel view of upside for Insmed
ADMS Adamas Pharmaceuticals
$6.52 /

+0.37 (+6.02%)

11/08/19 JMP Securities
Adamas Pharmaceuticals price target lowered to $16 from $57 at JMP Securities
09/30/19 BofA
Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill
09/30/19 BofA
Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill
09/09/19
Fly Intel: Top five analyst initiations
AXGT Axovant
$5.12 /

-0.19 (-3.58%)

08/12/19 Baird
Axovant upgraded to Outperform at Baird
08/12/19 Baird
Axovant upgraded to Outperform from Neutral at Baird
06/21/19 SVB Leerink
Axovant initiated with an Outperform at SVB Leerink
06/06/19 JMP Securities
Axovant price target raised to $28 after reverse split at JMP Securities
BCEL Atreca
$13.29 /

+3.185 (+31.53%)

09/04/19 Roth Capital
Atreca initiated with a Buy at Roth Capital
07/15/19
Fly Intel: Top five analyst initiations
07/15/19 Cowen
Atreca initiated with an Outperform at Cowen
07/15/19 Canaccord
Atreca initiated with a Buy at Canaccord
MYOV Myovant Sciences
$18.56 /

-0.62 (-3.23%)

11/19/19 Goldman Sachs
Myovant Sciences price target raised to $20 from $18 at Goldman Sachs
11/19/19 JMP Securities
JMP boosts Myovant price target to $34 after 'compelling' prostate cancer data
08/28/19
Fly Intel: Top five analyst initiations
08/28/19 Goldman Sachs
Slower Orilissa ramp has minimal impact on Neurocrine, says Goldman Sachs
PIRS Pieris Pharmaceuticals
$3.90 /

-0.24 (-5.80%)

07/30/19 Baird
Pieris Pharmaceuticals downgraded to Neutral from Outperform at Baird
07/29/19 William Blair
Updates 'very positive' for upcoming Pieris presentation, says William Blair
05/14/19 Baird
Pieris Pharmaceuticals initiated with an Outperform at Baird
05/13/19 Baird
Pieris Pharmaceuticals initiated with an Outperform at Baird
MYL Mylan
$18.53 /

-0.145 (-0.78%)

11/19/19 Morgan Stanley
Mylan only IPR challenger remaining for Biogen's Tecfidera, says Morgan Stanley
11/07/19
Fly Intel: Top five analyst downgrades
11/07/19 Morgan Stanley
Mylan downgraded to Equal Weight on growth uncertainty at Morgan Stanley
11/07/19 Morgan Stanley
Mylan downgraded to Equal Weight from Overweight at Morgan Stanley
RCKT Rocket Pharmaceuticals
$18.34 /

+0.38 (+2.12%)

11/18/19 Piper Sandler
Rocket may be next leading lentiviral vector company, says Piper Jaffray
11/07/19 Piper Sandler
Rocket Pharmaceuticals data by year-end to boost shares, says Piper Jaffray
11/05/19 Chardan
Rocket Pharmaceuticals initiated with a Buy at Chardan
10/24/19 Piper Sandler
Rocket Pharmaceuticals data update 'incrementally positive,' says Piper Jaffray
CBAY CymaBay
$1.67 /

+0.05 (+3.09%)

11/26/19 H.C. Wainwright
Favorable safety a positive for Genfit's elafibranor, says H.C. Wainwright
11/26/19
Fly Intel: Top five analyst downgrades
11/26/19 Roth Capital
CymaBay downgraded to Neutral from Buy at Roth Capital
11/26/19 Raymond James
CymaBay double downgraded at Raymond James after seladelpar setback
NBIX Neurocrine
$117.59 /

+0.77 (+0.66%)

11/05/19 Piper Sandler
Neurocrine price target raised to $116 from $111 at Piper Jaffray
10/04/19 Guggenheim
Guggenheim positively biased on Biotech heading into earnings
09/25/19 RBC Capital
Neurocrine approval in Huntington's could add upside, says RBC Capital
TCDA Tricida
$39.53 /

-0.5 (-1.25%)

06/27/19 Goldman Sachs
Goldman starts 'potential game-changer' Tricida with Buy, $48 price target
06/26/19 Goldman Sachs
Tricida initiated with a Buy at Goldman Sachs
05/24/19 Needham
Tricida initiated with a Buy at Needham
04/01/19 Empire
Tricida price target raised to $58 from $37 at Empire
NTLA Intellia Therapeutics
$17.08 /

+0.03 (+0.18%)

12/03/19 Raymond James
Audentes downgraded to Market Perform from Outperform at Raymond James
11/01/19 Raymond James
Intellia Therapeutics upgraded to Outperform at Raymond James
11/01/19 Raymond James
Intellia upgraded to Outperform from Market Perform at Raymond James
07/09/19
Fly Intel: Top five analyst initiations
ALKS Alkermes
$20.26 /

-0.29 (-1.41%)

11/18/19 Piper Sandler
Alkermes deal strengthens early-stage pipeline, says Piper Jaffray
11/18/19 Stifel
Alkermes made 'nice strategic move' in buying Rodin, says Stifel
11/11/19 Morgan Stanley
Alkermes data at SITC too early to assess 4230 potential, says Morgan Stanley
11/01/19 H.C. Wainwright
Alkermes price target lowered to $26 from $28 at H.C. Wainwright

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.